https://endpts.com/pfizer-details-mrna-flu-vaccine-data-but-revises-timeline/
0
0
10/31/23 at 11:46am
Organization
Endpoints News
Author
Nicole DeFeudis
56 words
0
Comments
Pfizer’s mRNA flu vaccine met both primary endpoints in the 18- to 64-year-old population in an ongoing Phase III trial, the company announced on Tuesday morning. However, executives are no longer shooting for a 2024 launch. While Pfizer initially pegged a po…
You are the first to view
Create an account
or login to join the discussion